Since ER+ and ER- breast cancers differ in 5 year survival rates [41, 42], we next determined if the 8 FFPE-derived regulons provide improved correlation with patient outcomes compared to single-gene analysis. The gene discussed is ESR1; the disease is breast carcinoma.